

14 June 2007

## **IMPORTANT PRESCRIBING INFORMATION**

Dear Healthcare Professional:

GlaxoSmithKline (GSK) would like to advise you that a new formulation of ELTROXIN™ Tablets (levothyroxine sodium) 50 micrograms and 100 micrograms will be available on or about 30 June 2007. The new formulation of Eltroxin Tablets will replace lactose with microcrystalline cellulose to improve the stability of the product and ensure continuity of supply globally.

The new 50mcg tablets will still be white, but not scored. The new 100mcg tablets will be white and not scored (the currently available 100mcg tablets are yellow and scored). As the new formulation tablets are not scored, please refer to the Eltroxin Data Sheet for guidance to achieve dose adjustment.

Eltroxin Tablets are indicated for the treatment of hypothyroidism and in common with all levothyroxine sodium products have a narrow therapeutic index. Due to pharmacokinetic variability between patients, there may be some patients who could experience a change in clinical effect when switched to different drug product brands or formulations.

## **RECOMMENDATIONS**

- Advise patients that from the end of June 2007 onwards, their Eltroxin Tablets may look different.
- Provide patients with tear-off tablet identification guide which will be posted to you in due course.
- Eltroxin Tablets, in common with all levothyroxine sodium products, have a narrow therapeutic index and therefore prescribers should be vigilant for symptoms suggestive of adverse reactions or loss of clinical control in patients using the new Eltroxin Tablets. Dose adjustments and monitoring of thyroid hormone levels may be necessary.
- Ask patients to promptly report any changes in their clinical condition.

If you have any further questions or wish to discuss this letter, please contact **GSK's Medical Information Line on 0800 808 500**.

Yours sincerely,



Gerard Cudmore MBBS  
Associate Medical Director  
Australasia and Asia Pacific

Eltroxin is a trademark of the GlaxoSmithKline group of companies. Marketed in New Zealand by GlaxoSmithKline NZ Limited, Auckland.